

# Teva Specialty Pipeline

Phase 2	Phase 3	Registration	Approved in 2017
Funapide (TV-45070, Nav1.7) <i>Neuropathic pain</i>	Fremanezumab (anti CGRP) <i>Chronic migraine (Global)</i>	Austedo <sup>®</sup> <i>Tardive dyskinesia (U.S.)</i>	Vantrela <sup>®</sup> ER <i>Pain (U.S.)</i>
Fasinumab ** <i>Chronic Lower Back Pain</i>	Fremanezumab (anti CGRP) <i>Episodic migraine (Global)</i>	QVAR <sup>®</sup> (beclomethasone dipropionate BAI) <i>Asthma (U.S.)</i>	Austedo <sup>®</sup> <i>Huntington Disease (U.S.)</i>
Laquinimod <i>Multiple sclerosis (primary progressive)</i>	Fremanezumab (anti CGRP) <i>Cluster Headache (Global)</i>	Reslizumab* IV <i>Asthma (Growth Markets)</i>	ArmonAir <sup>®</sup> RespiClick <sup>®</sup> <i>Asthma (U.S.)</i>
Laquinimod <i>Huntington disease</i>	Fasinumab ** <i>Osteoarthritis pain (Global)</i>	Fluticasone Propionate MDPI <i>Asthma (Growth markets)</i>	AirDuo <sup>®</sup> RespiClick <sup>®</sup> <i>Asthma (U.S.)</i>
Pridopidine <i>Huntington disease</i>	Reslizumab* SC <i>Asthma (Global)</i>	Fluticasone Salmeterol MDPI <i>Asthma (Growth markets)</i>	
	CT-P10 *** <i>Biosimilar (Rituxan<sup>®</sup> U.S.)</i>		
	CT-P6 *** <i>Biosimilar (Herceptin<sup>®</sup> U.S.)</i>		

**17 programs in phase 2 through Submission, 26 products in phase 1 or planned IND by 2019**

■ Migraine & Pain

■ Neurology & neuropsychiatry

■ Respiratory

■ Biosimilars

6

4

5

2

1

Note: Pipeline is current as of May 1st, 2017.

\* Approved in the U.S under the trade name: CINQAIR<sup>®</sup> \*\*In partnership with Regeneron \*\*\* In partnership with Celltrion